# A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status

> **NCT03665402** · NA · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 16 (actual)

## Conditions studied

- Tuberculosis
- Drug-Induced Liver Injury
- Adverse Drug Event

## Interventions

- **DRUG:** Isoniazid

## Key facts

- **NCT ID:** NCT03665402
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-13
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-03-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03665402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03665402, "A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03665402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*